US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
GB0423653D0
(en)
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
UA95902C2
(ru)
|
2005-02-23 |
2011-09-26 |
Дженентек, Инк. |
Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
|
CN105012953B
(zh)
|
2005-07-25 |
2018-06-22 |
阿普泰沃研发有限责任公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
RU2487888C2
(ru)
|
2006-06-12 |
2013-07-20 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи |
Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
|
ES2477497T3
(es)
|
2007-03-02 |
2014-07-17 |
Genentech, Inc. |
Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
|
GB0721095D0
(en)
*
|
2007-10-26 |
2007-12-05 |
Piramed Ltd |
Pharmaceutical compounds
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
PL2254571T3
(pl)
*
|
2008-03-18 |
2015-11-30 |
Genentech Inc |
Kombinacje koniugatu przeciwciała anty-HER2-lek i środki chemioterapeutyczne oraz sposoby zastosowania
|
ATE513856T1
(de)
|
2008-04-11 |
2011-07-15 |
Emergent Product Dev Seattle |
Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
TWI378933B
(en)
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
PL2385832T3
(pl)
|
2009-01-08 |
2016-01-29 |
Curis Inc |
Inhibitory 3-kinazy fosfoinozytydowej z grupą wiążącą cynk
|
WO2010105008A2
(en)
*
|
2009-03-12 |
2010-09-16 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
|
JP5567136B2
(ja)
*
|
2009-09-08 |
2014-08-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
4−置換ピリジン−3−イル−カルボキサミド化合物及び使用方法
|
RU2595718C2
(ru)
*
|
2009-09-09 |
2016-08-27 |
Селджен Авиломикс Рисерч,Инк. |
Ингибиторы pi3-киназы и их применение
|
PE20121816A1
(es)
*
|
2009-10-12 |
2013-01-02 |
Hoffmann La Roche |
Combinaciones de un inhibidor de pi3k y un inhibidor de mek
|
TW201129380A
(en)
*
|
2009-12-04 |
2011-09-01 |
Genentech Inc |
Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
|
AU2010338038B2
(en)
|
2009-12-31 |
2015-07-09 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Tricyclic compounds for use as kinase inhibitors
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
EP2552428A1
(en)
|
2010-03-30 |
2013-02-06 |
Novartis AG |
Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
|
EP2558864A1
(en)
*
|
2010-04-16 |
2013-02-20 |
Genentech, Inc. |
Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
US9586996B2
(en)
|
2010-04-30 |
2017-03-07 |
Esperance Pharmaceuticals, Inc. |
Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
|
EP2580320B1
(en)
|
2010-06-14 |
2018-08-01 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
PT2606070T
(pt)
|
2010-08-20 |
2017-03-31 |
Novartis Ag |
Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
|
US20120082647A1
(en)
*
|
2010-10-01 |
2012-04-05 |
Baker Darren P |
Interferon-beta for use as monotherapy or in combination with other cancer therapies
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
US20130266590A1
(en)
|
2010-12-13 |
2013-10-10 |
Novartis Ag |
Dimeric iap inhibitors
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
JP6147246B2
(ja)
|
2011-04-01 |
2017-06-14 |
ジェネンテック, インコーポレイテッド |
Akt及びmek阻害剤化合物の組み合わせ、及び使用方法
|
SI2694075T1
(sl)
|
2011-04-01 |
2016-07-29 |
Curis, Inc. |
Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink
|
EP2714046A1
(en)
*
|
2011-06-03 |
2014-04-09 |
F.Hoffmann-La Roche Ag |
Methods of treating mesothelioma with a pi3k inhibitor compound
|
JP2014520858A
(ja)
|
2011-07-13 |
2014-08-25 |
ノバルティス アーゲー |
タンキラーゼ阻害剤として用いるための新規な2−ピペリジン−1−イル−アセトアミド化合物
|
US9163003B2
(en)
|
2011-07-13 |
2015-10-20 |
Novartis Ag |
4-piperidinyl compounds for use as tankyrase inhibitors
|
EP2731951B1
(en)
|
2011-07-13 |
2015-08-19 |
Novartis AG |
4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
WO2013019620A2
(en)
*
|
2011-07-29 |
2013-02-07 |
Glaxosmithkline Llc |
Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
|
EP2766011B1
(en)
|
2011-10-13 |
2017-09-27 |
Genentech, Inc. |
Treatment of pharmacological-induced hypochlorhydria in cancer patients
|
IL301603A
(en)
|
2011-10-14 |
2023-05-01 |
Genentech Inc |
Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
|
WO2013071264A1
(en)
*
|
2011-11-11 |
2013-05-16 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
SG11201402739YA
(en)
|
2011-12-05 |
2014-06-27 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
US20140329858A1
(en)
|
2011-12-05 |
2014-11-06 |
Novartis Ag |
Cyclic Urea Derivatives As Androgen Receptor Antagonists
|
MX362521B
(es)
|
2011-12-05 |
2019-01-22 |
Novartis Ag |
Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3).
|
CA2860676A1
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
WO2013182668A1
(en)
|
2012-06-08 |
2013-12-12 |
F. Hoffmann-La Roche Ag |
Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
MX349551B
(es)
*
|
2012-10-10 |
2017-08-02 |
Hoffmann La Roche |
Proceso para preparar compuestos tienopirimidinas.
|
JP6243918B2
(ja)
|
2012-10-16 |
2017-12-06 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
Pkm2調節因子およびそれらの使用方法
|
CN104968363A
(zh)
*
|
2012-12-07 |
2015-10-07 |
综合医院公司 |
Pi3k/akt抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
|
US9321746B2
(en)
|
2013-02-19 |
2016-04-26 |
Novartis Ag |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
CN105358576B
(zh)
|
2013-02-20 |
2020-05-05 |
诺华股份有限公司 |
使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
CN108997225A
(zh)
|
2013-03-14 |
2018-12-14 |
特雷罗药物股份有限公司 |
Jak2和alk2抑制剂及其使用方法
|
US9498543B2
(en)
|
2013-03-15 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
CA3071678A1
(en)
|
2013-04-16 |
2014-10-23 |
Genentech,Inc. |
Pertuzumab variants and evaluation thereof
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
AU2015249633B2
(en)
|
2014-04-25 |
2020-10-15 |
Genentech, Inc. |
Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
|
CN106456776A
(zh)
|
2014-05-21 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
用PI3K抑制剂Pictilisib治疗PR阳性腔性A乳腺癌的方法
|
ES2686549T3
(es)
*
|
2014-06-16 |
2018-10-18 |
Worldwide Innovative Network |
Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
|
ES2729202T3
(es)
|
2014-07-16 |
2019-10-30 |
Dana Farber Cancer Inst Inc Et Al |
Inhibición de HER3 en cánceres ováricos serosos de grado bajo
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
US10238748B2
(en)
|
2014-08-12 |
2019-03-26 |
Novartis Ag |
Anti-CDH6 antibody drug conjugates
|
US9993551B2
(en)
|
2014-09-13 |
2018-06-12 |
Novartis Ag |
Combination therapies of EGFR inhibitors
|
ES2774448T3
(es)
|
2014-10-03 |
2020-07-21 |
Novartis Ag |
Terapias de combinación
|
CA2967188A1
(en)
|
2014-11-14 |
2016-05-19 |
Novartis Ag |
Antibody drug conjugates
|
MA40110B2
(fr)
*
|
2014-12-11 |
2020-12-31 |
Natco Pharma Ltd |
Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux
|
WO2016092508A1
(en)
|
2014-12-12 |
2016-06-16 |
Massachusetts General Hospital |
Treatment of breast cancer brain metastases
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
US9580437B2
(en)
|
2014-12-23 |
2017-02-28 |
Novartis Ag |
Triazolopyrimidine compounds and uses thereof
|
CN107667092B
(zh)
|
2015-03-25 |
2021-05-28 |
诺华股份有限公司 |
作为fgfr4抑制剂的甲酰化n-杂环衍生物
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
CN107614015A
(zh)
|
2015-05-30 |
2018-01-19 |
豪夫迈·罗氏有限公司 |
治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
JP6878316B2
(ja)
|
2015-06-19 |
2021-05-26 |
ノバルティス アーゲー |
Shp2の活性を阻害するための化合物および組成物
|
CN107922388B
(zh)
|
2015-06-19 |
2020-12-29 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
US10975080B2
(en)
|
2015-06-19 |
2021-04-13 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
AU2016287189A1
(en)
|
2015-06-29 |
2017-10-12 |
F. Hoffmann-La Roche Ag |
Methods of treatment with taselisib
|
CN105147696A
(zh)
*
|
2015-07-08 |
2015-12-16 |
李荣勤 |
联合使用盐酸二甲双胍和gdc0941的抗乳腺癌颗粒剂及制备方法
|
GB201514760D0
(en)
*
|
2015-08-19 |
2015-09-30 |
Karus Therapeutics Ltd |
Compounds and method of use
|
CA2999138C
(en)
|
2015-09-21 |
2024-05-21 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
WO2017093905A1
(en)
|
2015-12-03 |
2017-06-08 |
Novartis Ag |
Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna
|
DK3452465T3
(da)
|
2016-05-04 |
2021-02-08 |
Genoscience Pharma |
Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
|
PL3468972T3
(pl)
|
2016-06-14 |
2020-11-16 |
Novartis Ag |
Związki i kompozycje do hamowania aktywności shp2
|
WO2017219948A1
(en)
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Crystalline forms of triazolopyrimidine compound
|
JP2019522049A
(ja)
|
2016-06-20 |
2019-08-08 |
ノバルティス アーゲー |
トリアゾロピリジン化合物及びその使用
|
EP3472166A1
(en)
|
2016-06-20 |
2019-04-24 |
Novartis AG |
Imidazopyrimidine compounds useful for the treatment of cancer
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
JP2019536471A
(ja)
|
2016-09-27 |
2019-12-19 |
セロ・セラピューティクス・インコーポレイテッドCERO Therapeutics, Inc. |
キメラエンガルフメント受容体分子
|
US11246929B2
(en)
|
2016-12-19 |
2022-02-15 |
Merck Patent Gmbh |
Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
|
CA3048217A1
(en)
|
2016-12-22 |
2018-06-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3562844A1
(en)
|
2016-12-28 |
2019-11-06 |
Genentech, Inc. |
Treatment of advanced her2 expressing cancer
|
KR20210134432A
(ko)
|
2017-01-17 |
2021-11-09 |
제넨테크, 인크. |
피하 her 2 항체 제형
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
EP3589661B1
(en)
|
2017-03-02 |
2023-11-01 |
Genentech, Inc. |
Adjuvant treatment of her2-positive breast cancer
|
US11179413B2
(en)
|
2017-03-06 |
2021-11-23 |
Novartis Ag |
Methods of treatment of cancer with reduced UBB expression
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
KR20190140952A
(ko)
|
2017-04-24 |
2019-12-20 |
제넨테크, 인크. |
막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
JP2020520665A
(ja)
|
2017-05-24 |
2020-07-16 |
ノバルティス アーゲー |
抗体−サイトカイングラフト化タンパク質及び癌の治療における使用方法
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
WO2018215938A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
EP3661924A1
(en)
|
2017-07-31 |
2020-06-10 |
The Trustees of Columbia University in the City of New York |
Compounds, compositionals, and methods for treating t-cell acute lymphoblastic leukemia
|
US20200283444A1
(en)
*
|
2017-08-02 |
2020-09-10 |
Northwestern University |
Substituted fused pyrimidine compounds and uses thereof
|
IL293443A
(en)
|
2017-09-08 |
2022-07-01 |
Amgen Inc |
kras g12c inhibitors and methods of using them
|
CA3074304A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
|
WO2019067328A1
(en)
|
2017-09-26 |
2019-04-04 |
Cero Therapeutics, Inc. |
CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE
|
CN108187055B
(zh)
*
|
2018-03-06 |
2019-12-27 |
北京大学 |
一种具有协同增效作用的抗癌组合物
|
MX2020010241A
(es)
|
2018-03-28 |
2020-10-16 |
Cero Therapeutics Inc |
Composiciones de inmunoterapia celular y usos de las mismas.
|
WO2019191334A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
CA3093969A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
AU2019247498A1
(en)
|
2018-04-05 |
2020-11-26 |
Sumitomo Pharma Oncology, Inc. |
AXL kinase inhibitors and use of the same
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
JP7361722B2
(ja)
|
2018-05-04 |
2023-10-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及び同一物の使用方法
|
JP7361720B2
(ja)
|
2018-05-10 |
2023-10-16 |
アムジエン・インコーポレーテツド |
がんの治療のためのkras g12c阻害剤
|
ES2938987T3
(es)
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
JP7357644B2
(ja)
|
2018-06-11 |
2023-10-06 |
アムジエン・インコーポレーテツド |
がんを処置するためのkras g12c阻害剤
|
MA51848A
(fr)
|
2018-06-12 |
2021-04-21 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
PE20210405A1
(es)
|
2018-07-10 |
2021-03-02 |
Novartis Ag |
Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteina con dedos de zinc 2 de la familia ikaros (ikzf2)
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020023910A1
(en)
|
2018-07-26 |
2020-01-30 |
Tolero Pharmaceuticals, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
BR112021002632A2
(pt)
|
2018-08-17 |
2021-05-11 |
Novartis Ag |
compostos e composições de ureia como inibidores de smarca2/brm atpase
|
BR112021004371A2
(pt)
|
2018-09-11 |
2021-05-25 |
Curis Inc. |
terapia em combinação com um inibidor de fosfoinositídeo 3-quinase com uma porção de ligação a zinco
|
CA3113233A1
(en)
|
2018-09-18 |
2020-03-26 |
Nikang Therapeutics, Inc. |
Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
|
EP3856349A1
(en)
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
CN113382986A
(zh)
|
2018-09-25 |
2021-09-10 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
EP3856345A1
(en)
|
2018-09-29 |
2021-08-04 |
Novartis AG |
Process of manufacture of a compound for inhibiting the activity of shp2
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
MA55136A
(fr)
|
2018-11-19 |
2022-02-23 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
MX2021007157A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Heteroarilamidas utiles como inhibidores de kif18a.
|
AU2019403488A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
KIF18A inhibitors
|
EA202191730A1
(ru)
|
2018-12-20 |
2021-08-24 |
Эмджен Инк. |
Ингибиторы kif18a
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
PE20211296A1
(es)
|
2018-12-21 |
2021-07-20 |
Novartis Ag |
Anticuerpos anti-pmel17 y conjugados de los mismos
|
CN113412262A
(zh)
|
2019-02-12 |
2021-09-17 |
大日本住友制药肿瘤公司 |
包含杂环蛋白激酶抑制剂的制剂
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
EP3924054A1
(en)
|
2019-02-15 |
2021-12-22 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
WO2020180770A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
EP3931195A1
(en)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
CN113747895A
(zh)
|
2019-03-22 |
2021-12-03 |
大日本住友制药肿瘤公司 |
包含pkm2调节剂的组合物和用其治疗的方法
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
EP3994132A1
(en)
|
2019-07-03 |
2022-05-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
AU2020326627A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
MX2022001181A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
EP4007753A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a inhibitors
|
AU2020325115A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
Pyridine derivatives as KIF18A inhibitors
|
BR112022002518A2
(pt)
|
2019-08-15 |
2022-07-19 |
Black Diamond Therapeutics Inc |
Compostos de alquinila quinazolina
|
EP4031542A4
(en)
|
2019-09-18 |
2023-10-25 |
Merck Sharp & Dohme LLC |
KRAS G12C MUTANT SMALL MOLECULE INHIBITORS
|
WO2021057853A1
(en)
|
2019-09-26 |
2021-04-01 |
Novartis Ag |
Aza-quinoline compounds and uses thereof
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
US20240139193A1
(en)
|
2019-10-15 |
2024-05-02 |
Amgen Inc. |
Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
|
WO2021081212A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
KR20220106980A
(ko)
|
2019-10-28 |
2022-08-01 |
머크 샤프 앤드 돔 코포레이션 |
Kras g12c 돌연변이체의 소분자 억제제
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
EP4055028A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
KR20220109408A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
CN115873020A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
CN114901662A
(zh)
|
2019-11-08 |
2022-08-12 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の改善された合成
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
WO2021126816A1
(en)
|
2019-12-16 |
2021-06-24 |
Amgen Inc. |
Dosing regimen of a kras g12c inhibitor
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
CN111057065B
(zh)
*
|
2019-12-24 |
2021-04-23 |
沈阳药科大学 |
噻吩并嘧啶类化合物的制备方法和用途
|
BR112022010086A2
(pt)
|
2020-01-07 |
2022-09-06 |
Revolution Medicines Inc |
Dosagem do inibidor de shp2 e métodos de tratamento de câncer
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
US20230174518A1
(en)
|
2020-04-24 |
2023-06-08 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
US20240150358A1
(en)
*
|
2020-06-03 |
2024-05-09 |
Kineta, Inc. |
Purines and methods of their use
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
EP4183395A1
(en)
|
2020-07-15 |
2023-05-24 |
Taiho Pharmaceutical Co., Ltd. |
Pyrimidine compound-containing combination to be used in tumor treatment
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
JP2023541236A
(ja)
|
2020-09-03 |
2023-09-29 |
レボリューション メディシンズ インコーポレイテッド |
Shp2変異を有する悪性腫瘍を治療するためのsos1阻害剤の使用
|
TW202227460A
(zh)
|
2020-09-15 |
2022-07-16 |
美商銳新醫藥公司 |
Ras抑制劑
|
AU2021345423A1
(en)
|
2020-09-21 |
2023-05-11 |
Prelude Therapeutics, Incorporated |
Cdk inhibitors and their use as pharmaceuticals
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
CN117396472A
(zh)
|
2020-12-22 |
2024-01-12 |
上海齐鲁锐格医药研发有限公司 |
Sos1抑制剂及其用途
|
EP4267575A1
(en)
|
2020-12-22 |
2023-11-01 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
JP2024507996A
(ja)
|
2021-02-26 |
2024-02-21 |
ケロニア セラピューティクス, インコーポレイテッド |
リンパ球を標的とするレンチウイルスベクター
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
BR112023021111A2
(pt)
|
2021-04-13 |
2023-12-19 |
Nuvalent Inc |
Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2
|
JP2024517409A
(ja)
|
2021-04-16 |
2024-04-22 |
ノバルティス アーゲー |
抗体薬物結合体及びその作成方法
|
AU2022270116A1
(en)
|
2021-05-05 |
2023-12-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
EP4334325A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
EP4347041A1
(en)
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
WO2023284730A1
(en)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
EP4376874A1
(en)
|
2021-07-28 |
2024-06-05 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
US20230303509A1
(en)
|
2022-03-28 |
2023-09-28 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024023666A1
(en)
|
2022-07-26 |
2024-02-01 |
Novartis Ag |
Crystalline forms of an akr1c3 dependent kars inhibitor
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024102849A1
(en)
|
2022-11-11 |
2024-05-16 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|